Distress, disease, desire: perspectives on the medicalisation of premature ejaculation

Ylva Söderfeldt, Adam Droppe, Tim Ohnhäuser

Forskningsoutput: TidskriftsbidragArtikelPeer review

2 Citeringar (Scopus)


The discovery that certain selective serotonin reuptake inhibitors delay ejaculation and the later development and approval of dapoxetine as an on-demand treatment option has led to a dramatic increase in medical interest in premature ejaculation. This paper analyses the diagnostic criteria and the discussion within the medical community about suitable treatments against the backdrop of theories of science, sex and gender. Our conclusion is that the diagnosis itself and the suggested treatments contribute to normative models of sexual conduct and therefore reinforce the norms that cause patients' distress over ejaculating 'too soon'.

Sidor (från-till)865-866
Antal sidor1
TidskriftJournal of Medical Ethics
StatusPublicerad - 2017
Externt publiceradJa

Nationell ämneskategori

  • Farmakologi och toxikologi (30102)


Fördjupa i forskningsämnen för ”Distress, disease, desire: perspectives on the medicalisation of premature ejaculation”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här